SCHEDULE 13G/A 0001140361-24-008095 0001858703 XXXXXXXX LIVE 2 Common Stock, par value $0.001 per share 12/31/2025 0001374690 Larimar Therapeutics, Inc. 517125100 Three Bala Plaza East. Suite 506 Bala Cynwyd PA 19004 Rule 13d-1(b) Blue Owl Capital Holdings LP DE 8464663 0 8464663 0 8464663 9.99 PN The reported securities represent (i) 6,823,690 shares of Common Stock and (ii) 1,640,973 shares of Common Stock issuable upon conversion of Series A Preferred Stock (as defined below). The percentage of class is calculated based upon 85,590,392 shares of Common Stock outstanding as of November 3, 2025, as reported on the Issuer's Form 10-Q filed with the Securities and Exchange Commission on November 5, 2025, as decreased by (i) 2,500,000 shares of the Issuer's Common Stock exchanged for Series A Convertible Preferred Stock, and increased by (ii) 1,640,973 shares of Common Stock issuable upon conversion of Series A Preferred Stock. Larimar Therapeutics, Inc. Three Bala Plaza East. Suite 506, Bala Cynwyd, PA, 19004 This statement is filed by the Blue Owl Capital Holdings LP, referred to herein as the "Reporting Person." 399 Park Avenue New York, New York 10022 See response to Item 4 on the cover page. N IA See response to Item 9 on the cover page. The reported securities include 6,823,690 shares of Common Stock and 1,640,973 shares of Common Stock issuable upon conversion of 250,000 shares of Series A convertible preferred stock (which would be convertible into 2,500,000 shares of Common Stock in the absence of a conversion blocker that limits the holder's benefit ownership to 9.9%). The filing of this statement shall not be construed as an admission that the Reporting Person is, for the purpose of Section 13(d) or 13(g) of the Exchange Act, the beneficial owner of any securities covered by this statement. See response to Item 11 on the cover page. See response to Item 5 on the cover page. See response to Item 6 on the cover page. See response to Item 7 on the cover page. See response to Item 8 on the cover page. Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Blue Owl Capital Holdings LP /s/ Karen Hager 02/12/2026